Recently published articles about Difficult to Treat Depression

Weekly Mind Reader: Daylight Doesn’t Matter
news

February 6, 2026

This week features a study that reveals that seasonal daylight exposure has no measurable effect on rTMS outcomes — alongside reassuring news about unwanted intrusive thoughts.
Weekly Mind Reader: When Antidepressants Fail
news

January 23, 2026

New Mayo Clinic guidance stresses patient care, while studies examine veterans’ cannabis use and reject lowering the DSM-5-TR mixed-features threshold.
Weekly Mind Reader: Ketamine Marks 25 Years
news

July 18, 2025

This week: clinicians tackle ketamine safety, a troubling fluoxetine case, and new hope for treatment-resistant depression.
ECT Shows Promise in Curbing Suicide in Hard-to-Treat Depression
news

June 17, 2025

A new meta-analysis shows that ECT not only outperforms antidepressants for treatment-resistant depression but also reduces mortality risk.
Weekly Mind Reader: Ketamine Concerns
news

May 30, 2025

This week, we uncover an unsettling ketamine trend, how AI might help diagnosis tardive dyskinesia, and new insights into psychosis.
Could Mindfulness Crack Treatment-Resistant Depression?
news

May 16, 2025

New research shows that Mindfulness-Based Cognitive Therapy offers an effective and cost-saving option for difficult-to-treat depression.

Recent JCP Articles on Difficult to Treat Depression

JCP
Surgical Interventions in Treatment Resistant Depression
Insights

October 7, 2024

Patricio Riva Posse, MD, discusses advanced surgical interventions for treatment-resistant depression, including vagus nerve and deep brain stimulation. This presentation explores relapse rates, alternative therapies, and the potential for...
JCP
Neurosteroids and Postpartum Depression
Insights

October 7, 2024

In this video, Samantha Meltzer-Brody, MD, MPH, discusses the use of brexanolone and zuranolone, novel neurosteroids for treating postpartum depression, focusing on their mechanisms, rapid efficacy, and clinical trial...
JCP
Algorithms for TRD Treatment Success
Insights

September 27, 2024

Dr. Nolan Williams delves into the innovative Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treating resistant depression. Explore groundbreaking research, clinical trials, and the transformative potential of personalized brain...

Recent PCC Articles on Difficult to Treat Depression

PCC
Transcranial Magnetic Stimulation in Primary Care
Rounds in the General Hospital

March 12, 2024

TMS is a safe, effective, and well-tolerated noninvasive neurotherapeutic procedure that utilizes a strong electromagnetic field to change brain activity in a targeted fashion to treat a variety of...
, , , et al
PCC
Intravenous Ketamine vs Intranasal Esketamine for TRD
Letter to the Editor

February 13, 2024

Dr Mansuri and colleagues compare the pros and cons of IV ketamine and intranasal esketamine for treatment-resistant depression.
, , , et al
PCC
Long-Term Preservation TMS for MDD
Case Report

December 14, 2023

Two cases provide a unique look at how remission of depression can be maintained over a long duration using scheduled treatments of preservation transcranial magnetic stimulation with progressively increasing...
, , , et al

The latest news on Difficult to Treat Depression

Featured Difficult to Treat Depression Research

JCP
Effects of Low-Dose Ketamine Infusion on Hopelessness and Suicidal Thoughts
Original Research

July 8, 2024

A single infusion of low-dose ketamine resulted in a brief (~4 hour) yet significant reduction in hopelessness.
, , , et al
JCP
Barriers to Esketamine Nasal Spray Use in Treatment-Resistant Depression
Original Research

May 6, 2024

Potential barriers to treatment with esketamine nasal spray include travel distance, insurance, low socioeconomic status, and minority communities.
, , , et al
JCP
Subcallosal Cingulate Gyrus Deep Brain Stimulation for TRD
Original Research

June 28, 2023

DBS targeting the subcallosal cingulate gyrus to treat depressive symptoms resulted in response and remission rates of 75% and 62.5%.
, , , et al
How Esketamine Combos Fight Treatment-Resistant Depression
news

April 2, 2025

New study shows that esketamine is effective when combined with SSRIs or SNRIs, producing different benefits for each combination.
FDA Approves Spravato Nasal Spray for Major Depressive Disorder
news

January 23, 2025

The FDA approved Johnson & Johnson’s Spravato nasal spray as the first standalone treatment for treatment-resistant depression.
Weekly Mind Reader: Antidepressants and Gender
news

December 6, 2024

This week, we dig into sex and antidepressants, a new approach to schizophrenia, and The Southwest Forum on Difficult to Treat Depression.
JCP
Difficult to Treat Depression: Focus on Approach, Algorithms, and Access
Academic Highlights

November 25, 2024

The Southwest Forum on Difficult to Treat Depression brought together 11 experts to discuss aspects of managing difficult-to-treat depression. This article presents highlights from the forum, covering such topics...
, , , et al
Esketamine Nasal Spray Offers Help for Treatment-Resistant Depression
news

October 15, 2024

Esketamine nasal spray offers relief for treatment-resistant depression, but geographic, socioeconomic, and financial barriers hinder access.
JCP
Optimizing Recovery: Comprehensive Care Pathways for Depression
Insights

October 7, 2024

In this video, Dr. Jay Fournier discusses the challenges of outpatient depression care, including access issues, placebo response, and maintaining sustained remission. He outlines a stepped approach to treatment...

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe